OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) Files An 8-K Other Events
Item 8.01. Other Events.

On April 19, 2017, OWC Pharmaceutical Research Corp. (the "Registrant") filed a Form 8-K announcing the appointment of Alon Sinai, Chief Operating Officer of Registrant’s wholly-owned Israeli subsidiary, One World Cannabis Ltd ("OWC Israel") since July 2014, as the new Interim Chief Executive Officer of OWC Israel, effective April 12, 2017, replacing Mr. Ziv Turner.

The purpose for filing this Form 8-K/A is to correct the disclosure regarding the circumstances of Mr. Turner’s departure as CEO of OWC Israel. On April 2, 2017, Mr. Turner submitted his resignation as CEO of OWC Israel to the Registrant. On April 6, 2017, OWC Israel notified Mr. Turner that: (i) his resignation had not been accepted by OWC Israel; and (ii) he had, in fact, been terminated "for cause" as CEO and a director of OWC Israel, effective April 6, 2017.

About OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP)

OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system.

OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) Recent Trading Information

OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) closed its last trading session up +0.043 at 0.812 with 1,704,256 shares trading hands.